Travere Therapeutics (TVTX) Current Deferred Revenue (2021 - 2024)

Travere Therapeutics has reported Current Deferred Revenue for 4 years, with the latest figure at $2.8 million in Q4 2024.

• For the quarter ending Q4 2024, Current Deferred Revenue fell 60.33% year-over-year to $2.8 million; the trailing twelve-month figure through Dec 2024 stood at $2.8 million (down 60.33% YoY), and the FY2024 full-year result was $2.8 million, down 60.33% from the prior year.
• Current Deferred Revenue for Q4 2024 stood at $2.8 million, down from $3.8 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $43.0 million in Q3 2021, with the low at $2.8 million in Q4 2024.
• Historically, Current Deferred Revenue has averaged $14.0 million across 4 years, with a median of $10.6 million in 2023.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue plunged 73.53% — and 2023, when it retreated 18.07%.
• Travere Therapeutics' Current Deferred Revenue stood at $36.6 million in 2021, then sank by 37.49% to $22.9 million in 2022, then tumbled by 69.02% to $7.1 million in 2023, then slumped by 60.33% to $2.8 million in 2024.
• The last three Current Deferred Revenue figures came in at $2.8 million (Q4 2024), $3.8 million (Q3 2024), and $5.4 million (Q2 2024), per Business Quant data.